BioCardia, Inc. announced on September 18, 2025, the pricing of a public offering of an aggregate of 4,800,000 shares of its common stock. The offering also includes short-term warrants to purchase up to 4,800,000 shares of common stock.
The combined public offering price is $1.25 per share and accompanying short-term warrant, with an exercise price of $1.25 per share. The gross proceeds from the offering are expected to be $6 million, with a potential additional $6 million if all short-term warrants are fully exercised.
The company intends to use the net proceeds from this offering for working capital and general corporate purposes, including advancing its investigational biotherapeutic candidates and biotherapeutic delivery partnering business. The offering is expected to close on or about September 19, 2025, subject to customary closing conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.